112 related articles for article (PubMed ID: 20097087)
1. The influences of age and co-morbidities on treatment decisions for patients with HER2-positive early breast cancer.
Ring A
Crit Rev Oncol Hematol; 2010 Nov; 76(2):127-32. PubMed ID: 20097087
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists.
Hurria A; Naeim A; Elkin E; Limaye S; Grover A; Hudis C; Pearce C; Robson M
Crit Rev Oncol Hematol; 2007 Mar; 61(3):255-60. PubMed ID: 17098441
[TBL] [Abstract][Full Text] [Related]
3. Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer.
Krzyzanowska MK; Regan MM; Powell M; Earle CC; Weeks JC
J Am Coll Surg; 2009 Feb; 208(2):202-9. PubMed ID: 19228531
[TBL] [Abstract][Full Text] [Related]
4. Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologists.
Hurria A; Wong FL; Pal S; Chung CT; Bhatia S; Mortimer J; Somlo G; Hurvitz S; Villaluna D; Naeim A
Oncologist; 2009 Sep; 14(9):883-90. PubMed ID: 19726455
[TBL] [Abstract][Full Text] [Related]
5. Retrospective study of the effect of comorbidity on use of adjuvant chemotherapy in older women with breast cancer in a tertiary care setting.
Hawfield A; Lovato J; Covington D; Kimmick G
Crit Rev Oncol Hematol; 2006 Sep; 59(3):250-5. PubMed ID: 16527489
[TBL] [Abstract][Full Text] [Related]
6. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective.
Kulkarni S; Hicks DG
Ann Surg Oncol; 2008 Jun; 15(6):1677-88. PubMed ID: 18398661
[TBL] [Abstract][Full Text] [Related]
7. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.
de Munck L; Schaapveld M; Siesling S; Wesseling J; Voogd AC; Tjan-Heijnen VC; Otter R; Willemse PH
Breast Cancer Res Treat; 2011 Aug; 129(1):229-33. PubMed ID: 21431871
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
Jahanzeb M
Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
[TBL] [Abstract][Full Text] [Related]
10. Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era.
Palmieri C; Shah D; Krell J; Gojis O; Hogben K; Riddle P; Ahmad R; Tat T; Fox K; Porter A; Mahmoud S; Kirschke S; Shousha S; Gudi M; Coombes RC; Leonard R; Cleator S
Clin Breast Cancer; 2011 Apr; 11(2):93-102. PubMed ID: 21569995
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant trastuzumab for HER2-positive early breast cancer.
Palmieri FM; Myatt CV; Perez EA
Clin J Oncol Nurs; 2010 Jun; 14(3):326-36. PubMed ID: 20529794
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab.
Chan A; McGregor SR
Intern Med J; 2012 Mar; 42(3):267-74. PubMed ID: 21241440
[TBL] [Abstract][Full Text] [Related]
13. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
Nishimura R; Okumura Y; Arima N
Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn.
Piccart-Gebhart MJ
Eur J Cancer; 2006 Aug; 42(12):1715-9. PubMed ID: 16806901
[TBL] [Abstract][Full Text] [Related]
16. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
17. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
18. Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States.
Danese MD; Lalla D; Brammer M; Doan Q; Knopf K
Cancer; 2010 Dec; 116(24):5575-83. PubMed ID: 20734398
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
McArthur HL; Mahoney KM; Morris PG; Patil S; Jacks LM; Howard J; Norton L; Hudis CA
Cancer; 2011 Dec; 117(24):5461-8. PubMed ID: 21681735
[TBL] [Abstract][Full Text] [Related]
20. Progress in systemic adjuvant therapy of early-stage breast cancer.
Gradishar WJ; O'Regan RM
Int J Clin Oncol; 2003 Aug; 8(4):239-47. PubMed ID: 12955580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
